Comparison of two viscoelastic testing devices in a porcine model of surgery, hemorrhage and resuscitation

Daniel Gruneberg, Maximilian Dietrich, Alexander Studier‐Fischer, Clara Petersen, Maik von der Forst, Berkin Özdemir, Herbert Schöchl, Felix Nickel, Markus A. Weigand, Felix C. F. SchmittFrontiers in Bioengineering and Biotechnology 2024 · DOI

Abstract

This research contributes valuable insights into the use of ClotPro® in porcine models of hemorrhage and coagulopathy, highlighting both its applicability and limitations in comparison to ROTEM® delta. The observed differences, especially in fibrin polymerization assays, emphasize the importance of understanding device-specific characteristics when interpreting results. Due to its inapplicability, TPA-test should not be used in porcine blood to evaluate fibrinolytic potential. The study provides a foundation for future investigations into the use of different viscoelastic hemostatic assays in porcine animal models.

Introduction

In emergency medicine, point-of-care (POC) testing is vital for treating coagulopathy—the failure of blood to clot properly during major trauma. Viscoelastic hemostatic assays (VHAs) provide a real-time "picture" of how a clot forms, how firm it is, and how quickly it dissolves. Because pigs are the primary animal model for human trauma and hemorrhage research, it is essential that the tools used in these studies are accurate and comparable across platforms.

The ROTEM® delta is the established industry standard, but the newer ClotPro® system offers different mechanics, such as active pipetting tips with dry reagents. This study aimed to determine if ClotPro results in pigs could be directly compared to ROTEM results, or if species-specific biological differences would affect the assays.

Methods

The researchers utilized a cohort of 27 healthy pigs (sus scrofa domestica) subjected to a rigorous experimental protocol designed to simulate clinical trauma:

  1. Major Surgery: An esophagectomy to simulate surgical trauma.
  2. Hemorrhage: Bloodletting until the Mean Arterial Pressure (MAP) dropped to 40 mmHg, inducing hemorrhagic shock.
  3. Resuscitation: Treatment with either fluids or norepinephrine.

Blood samples were taken at five timepoints and analyzed simultaneously on both ClotPro and ROTEM delta devices. The team compared several key assays: EX-test/EX-TEM (extrinsic pathway), IN-test/IN-TEM (intrinsic pathway), Fib-test/FIB-TEM (fibrinogen isolation), and the TPA-test (lysis induction).

Results

Extrinsic and Intrinsic Pathway Comparison

The study generated a primary experimental dataset from 26 eligible pigs. While clot firmness in the extrinsic (EX) tests showed strong correlation, clotting times (CT) did not. ClotPro consistently reported longer clotting times than ROTEM, meaning a "normal" value on one device might look "delayed" on the other. For values below 59 mm, ClotPro tended to report higher firmness than ROTEM.

Correlation and Bland-Altman plots for EX-test/EXTEM parameters including Clotting Time (CT) and Maximum Clot Firmness (MCF).

Similar trends were observed in the intrinsic pathway assays. While the correlation for clot firmness remained strong, the lack of interchangeability for clotting times suggests that researchers must exercise caution when comparing data across these two devices.

Correlation and Bland-Altman plots for IN-test/INTEM parameters, showing similar discrepancies in clotting time (CT) compared to the extrinsic pathway.

Fibrinogen and Lysis Discrepancies

One of the most significant findings involved fibrin polymerization. ClotPro’s Fib-test yielded markedly higher firmness values than ROTEM’s FIB-TEM, with a mean difference of +13 mm for MCF. This discrepancy is likely due to ClotPro's use of a dual-inhibitor approach (Cytochalasin D + Tirofiban) to inhibit platelets, whereas ROTEM uses only one. This suggests ClotPro might be more effective at isolating fibrin in porcine blood, or that pig platelets are resistant to ROTEM's specific inhibitor.

Furthermore, the ClotPro-exclusive TPA-test failed completely to induce significant lysis in porcine blood. Maximum lysis in the TPA-test was approximately 8.85%, which was identical to non-stimulated tests, failing to show the expected spike in clot breakdown.

Discussion and Conclusion

This study demonstrates that while ClotPro is a viable tool for porcine research, its results are not directly interchangeable with ROTEM delta. The significant differences in clotting times and fibrin measurements highlight the need for device-specific reference ranges in animal models.

The failure of the TPA-test suggests that porcine plasminogen may be resistant to the human recombinant TPA used in ClotPro reagents. Future work is required to develop porcine-specific reagents to accurately measure fibrinolytic potential. Researchers using these devices in swine models must be aware of these limitations to avoid misinterpreting coagulopathy data.

Summary updated

Abstract

This research contributes valuable insights into the use of ClotPro<sup>®</sup> in porcine models of hemorrhage and coagulopathy, highlighting both its applicability and limitations in comparison to ROTEM<sup>®</sup> delta. The observed differences, especially in fibrin polymerization assays, emphasize the importance of understanding device-specific characteristics when interpreting results. Due to its inapplicability, TPA-test should not be used in porcine blood to evaluate fibrinolytic potential. The study provides a foundation for future investigations into the use of different viscoelastic hemostatic assays in porcine animal models.
BibTeX
@inproceedings{gruneberg2024comparison,
  author = {Daniel Gruneberg and Maximilian Dietrich and Alexander Studier‐Fischer and Clara Petersen and Maik von der Forst and Berkin Özdemir and Herbert Schöchl and Felix Nickel and Markus A. Weigand and Felix C. F. Schmitt},
  title = {{Comparison of two viscoelastic testing devices in a porcine model of surgery, hemorrhage and resuscitation}},
  booktitle = {Frontiers in Bioengineering and Biotechnology},
  year = {2024},
  doi = {10.3389/fbioe.2024.1417847},
}
Figure